Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295 · see citing works

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,177 · see citing works

p53 is required for radiation-induced apoptosis in mouse thymocytes

Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,021 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

Control of apoptosis by p53

Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401 · see citing works

Is a p53-Regulated Inhibitor of G2/M Progression

Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251 · see citing works

p53 and Human Cancer: The First Ten Thousand Mutations

Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 980 · see citing works

Regulation ofp53downstream genes

El‐Deiry, W. S. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0097 · Cited by 797 · see citing works

Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · see citing works

Structure-based design of potent non-peptide MDM2 inhibitors

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · see citing works

MDMX: a novel p53‐binding protein with some functional properties of MDM2.

Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · see citing works

In vivo ubiquitination and proteasome-mediated degradation of p53(1).

Maki, C. G., Huibregtse, J. M., & Howley, P. M. (1996) · PubMed · Cited by 645 · see citing works

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · see citing works

Inactivation of the p53 pathway in retinoblastoma

Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595 · see citing works

Functions of the MDM2 oncoprotein

Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050273 · Cited by 573 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

Kojima, K., Konopleva, M. Y., Samudio, I. J., Shikami, M., Cabreira-Hansen, M. D. G., McQueen, T. J., Ruvolo, V. R., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407 · see citing works

Regulation and Significance of Apoptosis in the Stem Cells of the Gastrointestinal Epithelium

Potten, C. S., Wilson, J. W., & Booth, C. E. (1997) · Stem Cells · doi:10.1002/stem.150082 · Cited by 285 · see citing works

Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics

Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271 · see citing works

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo

Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256 · see citing works

MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin

Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600147200 · Cited by 236 · see citing works

<i>mdm2</i> Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation

Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234 · see citing works

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3

Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189 · see citing works

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · see citing works

Wild-Type p53: Tumors Can't Stand It

Kastan, M. B. (2007) · Cell · doi:10.1016/j.cell.2007.02.022 · Cited by 158 · see citing works

Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin

Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0200 · Cited by 140 · see citing works

Mutational spectrum of p53 mutations in primary breast and ovarian tumors

Feki, A., & Irminger-Finger, I. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.07.002 · Cited by 139 · see citing works

Strategies for therapeutic targeting of the p53 pathway in cancer

Wiman, K. G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401921 · Cited by 135 · see citing works

p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53

Chen, L., Yin, H. H., Farooqi, B., Sebti, S. M., Hamilton, A. D., & Chen, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0342 · Cited by 97 · see citing works

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia

Saddler, C. M., Ouillette, P. D., Kujawski, L. A., Shangary, S. K., Talpaz, M., Kaminski, M. S., Erba, H. P., Shedden, K., Wang, S., & Malek, S. N. (2007) · Blood · doi:10.1182/blood-2007-09-112698 · Cited by 96 · see citing works

p53 as a target for anti-cancer drug development

Bouchet, B. P., de Fromentel, C. C., Puisieux, A., & Galmarini, C. M. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.10.005 · Cited by 84 · see citing works

Structure and Organization of Amplified DNA on Double Minutes Containing the mdm2 Oncogene

Fakharzadeh, S. S., Rosenblum, L. S., Murphy, M. E., Hoffman, E. K., & George, D. L. (1993) · Genomics · doi:10.1006/geno.1993.1058 · Cited by 66 · see citing works

Gone but not forgotten

Sharpless, N. E., & DePinho, R. A. (2007) · Nature · doi:10.1038/nature05567 · Cited by 42 · see citing works

Application of radiobiologic principles to radiation therapy

Suit, H. D. (1968) · Cancer · doi:10.1002/1097-0142(196810)22:4 · Cited by 9 · see citing works

Apoptosis in cancer: from pathogenesis to treatment

Wong, R. S. (2011) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836 · see citing works

Modes of p53 regulation.

Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · see citing works

Brønsted-Acid-Catalyzed Asymmetric Multicomponent Reactions for the Facile Synthesis of Highly Enantioenriched Structurally Diverse Nitrogenous Heterocycles

Yu, J., Shi, F. J., & Gong, L. (2011) · Accounts of Chemical Research · doi:10.1021/ar2000343 · Cited by 905 · see citing works

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891 · see citing works

Awakening guardian angels: drugging the p53 pathway

Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · see citing works

Spirooxindoles: Promising scaffolds for anticancer agents

Yu, B., Yu, D., & Liu, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.056 · Cited by 870 · see citing works

Organocatalytic Asymmetric Assembly Reactions: Synthesis of Spirooxindoles via Organocascade Strategies

Cheng, D., Ishihara, Y., Tan, B., & Barbas, C. F. (2014) · ACS Catalysis · doi:10.1021/cs401172r · Cited by 855 · see citing works

The role of ubiquitination in tumorigenesis and targeted drug discovery

Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744 · see citing works

Evolving therapeutic landscape of advanced hepatocellular carcinoma

Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 740 · see citing works

Inhibition of α-helix-mediated protein–protein interactions using designed molecules

Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

Recent Advances in Asymmetric Organocatalytic Construction of 3,3′‐Spirocyclic Oxindoles

Hong, L., & Wang, R. (2013) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201200808 · Cited by 719 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works

Signaling to p53: ribosomal proteins find their way

Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591 · see citing works

Organocatalytic Synthesis of Spiro[pyrrolidin-3,3′-oxindoles] with High Enantiopurity and Structural Diversity

Chen, X., Wei, Q., Luo, S., Xiao, H., & Gong, L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja905302f · Cited by 577 · see citing works

Highly enantioselective synthesis and cellular evaluation of spirooxindoles inspired by natural products

Antonchick, A. P., Gerding‐Reimers, C., Catarinella, M., Schürmann, M., Preut, H., Ziegler, S., Rauh, D., & Waldmann, H. (2010) · Nature Chemistry · doi:10.1038/nchem.730 · Cited by 570 · see citing works

Catalytic Enantioselective 1,3-Dipolar Cycloadditions of Azomethine Ylides for Biology-Oriented Synthesis

Narayan, R., Potowski, M., Jia, Z., Antonchick, A. P., & Waldmann, H. (2014) · Accounts of Chemical Research · doi:10.1021/ar400286b · Cited by 486 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

Strategies for optimizing the response of cancer and normal tissues to radiation

Moding, E. J., Kastan, M. B., & Kirsch, D. G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4003 · Cited by 461 · see citing works

The p53 orchestra: Mdm2 and Mdmx set the tone

Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450 · see citing works

E3 ubiquitin ligases: styles, structures and functions

Yang, Q., Zhao, J., Chen, D., & Wang, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00043-2 · Cited by 435 · see citing works

Drugging the undruggables: exploring the ubiquitin system for drug development

Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427 · see citing works

The MDM2-p53 pathway revisited

Nag, S. A., Jiangjiang, Q., Kalkunte, S. S., Ming-hai, W., & Zhang, R. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414 · see citing works

Mitochondria-mediated apoptosis in mammals

Xiong, S., Mu, T., Wang, G., & Jiang, X. (2014) · Protein & Cell · doi:10.1007/s13238-014-0089-1 · Cited by 400 · see citing works

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391 · see citing works

Bee venom in cancer therapy

Oršolić, N. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9339-3 · Cited by 390 · see citing works

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works

Clinical and Molecular Spectrum of Liposarcoma

Lee, A. T. J., Thway, K., Huang, P. H., & Jones, R. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9598 · Cited by 381 · see citing works

Targeting the MDM2-p53 Interaction for Cancer Therapy

Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 364 · see citing works

The Tumor Suppressor p53: From Structures to Drug DiscoveryPreprint

Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 356 · see citing works

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328 · see citing works

p53 Family and Cellular Stress Responses in Cancer

Pflaum, J., Schlosser, S., & ller, M. M. ⁄. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 294 · see citing works

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

Zhao, Y., Yu, S., Sun, W., Liu, L., Lü, J., McEachern, D., Shargary, S., Bernard, D., Li, X., Zhao, T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4005708 · Cited by 292 · see citing works

Features of protein–protein interactions that translate into potent inhibitors: topology, surface area and affinity

Smith, M. C. P., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 285 · see citing works

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

Bernal, F., Wade, M. R., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 284 · see citing works

The ubiquitin proteasome system — Implications for cell cycle control and the targeted treatment of cancer

Bassermann, F. C., Eichner, R., & Pagano, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.02.028 · Cited by 268 · see citing works

Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future

Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 257 · see citing works

Targeting p53 for Novel Anticancer Therapy

Wang, Z., & Sun, Y. (2010) · Translational Oncology · doi:10.1593/tlo.09250 · Cited by 249 · see citing works

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245 · see citing works

Apoptosis in cancer: Key molecular signaling pathways and therapy targets

Burz, C. C., Berindan‐Neagoe, I., Bălăcescu, O., & Irimie, A. (2009) · Acta Oncologica · doi:10.1080/02841860902974175 · Cited by 244 · see citing works

p53-based Cancer TherapyPreprint

Lane, D. P., Cheok, C. F., & Laı́n, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 244 · see citing works

Role of p53 in breast cancer progression: An insight into p53 targeted therapy

Marvalim, C., Datta, A., & Lee, S. C. (2023) · Theranostics · doi:10.7150/thno.81847 · Cited by 243 · see citing works

SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells

Li, L., Osdal, T., Ho, Y., Chun, S., McDonald, T., Agarwal, P., Lin, A., Chu, S., Qi, J., Li, L., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.08.001 · Cited by 234 · see citing works

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors

Zhao, Y., Liu, L., Sun, W., Lu, J., McEachern, D., Li, X., Yu, S., Bernard, D., Ochsenbein, P., Ferey, V., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja3125417 · Cited by 234 · see citing works

Recent therapeutic trends and promising targets in triple negative breast cancer

Hwang, S., Park, S., & Kwon, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.006 · Cited by 233 · see citing works

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230 · see citing works

p53 as a target for the treatment of cancer

Duffy, M. J., Synnott, N. C., McGowan, P. M., Crown, J. P., O’Connor, D. P., & Gallagher, W. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.004 · Cited by 230 · see citing works

D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms

Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 229 · see citing works

The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap

Ellis, M. J., & Perou, C. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0462 · Cited by 227 · see citing works

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223 · see citing works

MDM2–p53 Pathway in Hepatocellular Carcinoma

Meng, X., Franklin, D. A., Dong, J., & Zhang, Y. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1446 · Cited by 216 · see citing works

Recent advances in organocatalytic asymmetric multicomponent cascade reactions for enantioselective synthesis of spirooxindoles

Wang, Y., Cobo, A. A., & Franz, A. K. (2021) · Organic Chemistry Frontiers · doi:10.1039/d1qo00220a · Cited by 216 · see citing works

Liposarcoma: Molecular Genetics and Therapeutics

Conyers, R. K., Young, S., & Thomas, D. M. (2010) · Sarcoma · doi:10.1155/2011/483154 · Cited by 213 · see citing works

Stapled Peptides with Improved Potency and Specificity That Activate p53

Brown, C. J., Quah, S. T., Jong, J., Goh, A. M., Chiam, P. C., Khoo, K. H., Choong, M. L., Lee, M. A., Yurlova, L., Zolghadr, K., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3005148 · Cited by 206 · see citing works

Therapeutic targeting of tumor suppressor genes

Morris, L. G. T., & Chan, T. A.-T. (2014) · Cancer · doi:10.1002/cncr.29140 · Cited by 201 · see citing works

Identification and Characterization of the First Small Molecule Inhibitor of MDMX

Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198 · see citing works

Targeting the ubiquitin–proteasome system for cancer therapy

Shen, M., Schmitt, S. M., Buac, D., & Dou, Q. P. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.815728 · Cited by 197 · see citing works

Protein-protein interaction modulators: advances, successes and remaining challenges

Mabonga, L., & Kappo, A. P. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00570-x · Cited by 196 · see citing works

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils

Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 192 · see citing works

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy

Li, Q., & Lozano, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 191 · see citing works

Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy

Ke, B., Tian, M., Li, J., Liu, B., & He, G. (2016) · Medicinal Research Reviews · doi:10.1002/med.21398 · Cited by 188 · see citing works

Recent Advances in p53 Research and Cancer Treatment

Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 187 · see citing works

p53 regulation by ubiquitin

Brooks, C. L., & Gu, W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.022 · Cited by 186 · see citing works

Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction

Yu, S., Qin, D., Shangary, S., Chen, J., Wang, G., Ding, K., McEachern, D., Qiu, S., Nikolovska-Coleska, Z., Miller, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901400z · Cited by 180 · see citing works

Checkpoint control and cancer

Medema, R. H., & Macůrek, L. (2011) · Oncogene · doi:10.1038/onc.2011.451 · Cited by 178 · see citing works

Targeting Apoptosis Pathways for New Cancer Therapeutics

Bai, L., & Wang, S. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 177 · see citing works

Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies

Micel, L. N., Tentler, J. J., Smith, P. G., & Eckhardt, G. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0958 · Cited by 176 · see citing works

Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX

Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173 · see citing works

The regulation of MDM2 oncogene and its impact on human cancers

Zhao, Y., Yu, H., & Hu, W. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt147 · Cited by 173 · see citing works

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170 · see citing works

Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

Rew, Y., Sun, D., de Turiso, F. G.-L., Bartberger, M. D., Beck, H. P., Canon, J. R., Chen, A., Chow, D. T., Deignan, J., Fox, B. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300354j · Cited by 166 · see citing works

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets Serious

Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201003863 · Cited by 166 · see citing works

Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment

Gupta, A., Shah, K., Oza, M. J., & Behl, T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.155 · Cited by 166 · see citing works

An Organocatalytic Cascade Strategy for the Enantioselective Construction of Spirocyclopentane Bioxindoles Containing Three Contiguous Stereocenters and Two Spiro Quaternary Centers

Sun, W., Zhu, G., Wu, C., Hong, L., & Wang, R. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201200478 · Cited by 165 · see citing works

Targeting the DNA Damage Response in Cancer

Ljungman, M. E. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 163 · see citing works

Exploring the multiple roles of guardian of the genome: P53

Feroz, W., & Sheikh, A. M. A. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00089-x · Cited by 161 · see citing works

An Easy Entry to Optically Active Spiroindolinones: Chiral Brønsted Acid‐Catalysed Pictet–Spengler Reactions of Isatins

Duce, S., Pesciaioli, F., Gramigna, L., Bernardi, L., Mazzanti, A., Ricci, A., Bartoli, G., & Bencivenni, G. (2011) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201100050 · Cited by 159 · see citing works

Current strategies to target p53 in cancer

Chen, F., Wang, W., & El‐Deiry, W. S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.031 · Cited by 158 · see citing works

Protein-peptide association kinetics beyond the seconds timescale from atomistic simulations

Paul, F., Wehmeyer, C., Abualrous, E. T., Wu, H., Crabtree, M., Schöneberg, J., Clarke, J., Freund, C., Weikl, T. R., & Noé, F. (2017) · Nature Communications · doi:10.1038/s41467-017-01163-6 · Cited by 158 · see citing works

Organocatalytic Michael–Alkylation Cascade: The Enantioselective Nitrocyclopropanation of Oxindoles

Pesciaioli, F., Righi, P., Mazzanti, A., Bartoli, G., & Bencivenni, G. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201003423 · Cited by 155 · see citing works

Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein−Protein Interaction: Structure−Activity Studies Leading to Improved Potency

Hardcastle, I. R., Liu, J., Valeur, E., Watson, A. F., Ahmed, S. U., Blackburn, T. J., Bennaceur, K., Clegg, W., Drummond, C. J., Endicott, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1011929 · Cited by 152 · see citing works

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works

Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics

Antao, A. M., Tyagi, A., Kim, K.-S., & Ramakrishna, S. (2020) · Cancers · doi:10.3390/cancers12061579 · Cited by 150 · see citing works

Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions

Li, C. V., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 146 · see citing works

MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme

Suh, S.-S., Yoo, J. Y., Nuovo, G. J., Jeon, Y.-J., Kim, S., Lee, T. J., Kim, T., Bakàcs, A., Alder, H., Kaur, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202465109 · Cited by 144 · see citing works

Targeting the ubiquitin pathway for cancer treatment

Liu, J., Shaik, S., Dai, X., Wu, Q., Zhou, X., Wang, Z. P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.11.005 · Cited by 144 · see citing works

Organocatalytic Diastereo‐ and Enantioselective 1,3‐Dipolar Cycloaddition of Azlactones and Methyleneindolinones

Sun, W., Zhu, G., Wu, C., Li, G., Hong, L., & Wang, R. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302831 · Cited by 144 · see citing works

Phosphine-Catalyzed [4 + 2] Annulation of γ-Substituent Allenoates: Facile Access to Functionalized Spirocyclic Skeletons

Li, E., Huang, Y. Q., Liang, L., & Xie, P. (2013) · Organic Letters · doi:10.1021/ol401249e · Cited by 144 · see citing works

Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists

Shen, H., & Maki, C. G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 143 · see citing works

Hot spot-based design of small-molecule inhibitors for protein–protein interactions

Guo, W., Wisniewski, J. A., & Ji, H. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.095 · Cited by 142 · see citing works

Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction

Plante, J. P., Burnley, T., Malkova, B., Webb, M. E., Warriner, S. L., Edwards, T. A., & Wilson, A. J. (2009) · Chemical Communications · doi:10.1039/b908207g · Cited by 141 · see citing works

Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator

Xiong, X., Zhao, Y., He, H., & Sun, Y. (2010) · Oncogene · doi:10.1038/onc.2010.569 · Cited by 141 · see citing works

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 140 · see citing works

Assembly of Spirooxindole Derivatives Containing Four Consecutive Stereocenters via Organocatalytic Michael–Henry Cascade Reactions

Albertshofer, K., Tan, B., & Barbas, C. F. (2012) · Organic Letters · doi:10.1021/ol300441z · Cited by 138 · see citing works

Superparamagnetic Iron Oxide Nanotheranostics for Targeted Cancer Cell Imaging and pH-Dependent Intracellular Drug Release

Zou, P., Yu, Y., Wang, Y. A., Zhong, Y., Welton, A. R., Galbán, C. J., Wang, S., & Sun, D. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100273t · Cited by 137 · see citing works

Inhibition of p53 inhibitors: progress, challenges and perspectives

Sanz, G., Singh, M., Peuget, S., & Selivanova, G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz075 · Cited by 137 · see citing works

Catalytic asymmetric 1,3-dipolar cycloaddition of N-unprotected 2-oxoindolin-3-ylidene derivatives and azomethine ylides for the construction of spirooxindole-pyrrolidines

Liu, T., Xue, Z.-Y., Tao, H., & Wang, C. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00943a · Cited by 136 · see citing works

Targeting p53 for enhanced radio- and chemo-sensitivity

Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 134 · see citing works

Targeting intrinsically disordered proteins at the edge of chaos

Ruan, H., Sun, Q., Zhang, W., Liu, Y., & Lai, L. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.017 · Cited by 133 · see citing works

Small-molecule approach to block p53-MDM2 interaction as a cancer therapeutic strategy

Wang, S. (2008) · Cancer Research

A novel orally active MDM2 inhibitor (MI-219) activates the p53 pathway and is selectively toxic to tumor cells

Shangary, S. K., Qin, D., McEachern, D., Miller, R. S., Nikolovska‐Coleska, Z., Liu, M., Qiu, S., Ding, K., Wang, G., Chen, J., et al. (2007) · Molecular Cancer Therapeutics · Cited by 1 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works